Primary Care/Hospitalist
RSSArticles
-
Generic Pre-Exposure Prophylaxis Set to Debut
Pre-exposure prophylaxis (PrEP), which consists of the anti-HIV drugs emtricitabine and tenofovir disoproxil fumarate (TDF/FTC, brand name Truvada), is recommended as a first-line resource in HIV prevention. A generic version of the drug combination is set to be released in 2020, which could expand access to PrEP in the United States.
-
Drug Studied for Treatment of Fibroid-Associated Bleeding
Elagolix, a gonadotropin-releasing hormone antagonist currently used in the treatment of endometriosis pain, is now being studied for treatment of uterine fibroids and heavy menstrual bleeding in women. The drug was approved by the FDA in July 2018 for the treatment of moderate to severe endometriosis pain.
-
Expanding Intrauterine Contraceptive Choices: Science Seeks Options
The copper T 380A intrauterine device (IUD), developed almost 50 years ago, was introduced in the United States in 1988. It is an extremely effective form of birth control. Researchers are conducting a clinical trial comparing the device with a newer, smaller copper IUD not sold in the United States.
-
Using Apple Cider Vinegar for Weight Management on a Restricted Diet
Supplementation with 30 mL of apple cider vinegar combined with a restricted calorie diet may decrease body weight, body mass index, and serum triglyceride levels in people with obesity.
-
Mindfulness Interventions for ADHD: Neurobiologic Antidote?
The current standard of care consists of behavioral interventions and stimulant medication; however, symptoms often are recalcitrant to these therapies and medication treatment has significant potential for undesirable effects. Functional neuroimaging studies support the premise that functional connectivity abnormalities in attention deficit hyperactivity disorder brains may be targeted directly and improved by mindfulness and meditation interventions.
-
Epilepsy Management in Primary Care
Epilepsy affects about 50 million people worldwide and is responsible for up to 0.5% of the global burden of disease. There are more than 5 million people diagnosed with epilepsy every year and that number is expected to continue to rise.
-
Icosapent Ethyl Capsules (Vascepa)
Icosapent is the first drug approved to reduce the risk of cardiovascular events in patients with established cardiovascular disease and hypertriglyceridemia on maximally tolerated statin therapy.
-
CNS Agents Emerge as Frontrunners in FDA-Approved Treatments for Low Libido in Women
Low libido is the most common sexual complaint, affecting up to 38.7% of women, with up to 12.3% also reporting significant distress associated with this condition. Debate continues about how female desire disorders are characterized, diagnosed, and treated.
-
The Risk of Endocarditis With Bacteremia
Interrogation of the Danish National Patient Registry revealed bacteremia due to Enterococcus faecalis was most likely to be associated with infective endocarditis; thus, echocardiography is warranted in these patients.
-
Fever of Unknown Origin Due to Cat Scratch Disease
Disseminated cat scratch disease may present as a fever of unknown origin.